Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 260

1.

Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions.

Padhani AR, Weinreb J, Rosenkrantz AB, Villeirs G, Turkbey B, Barentsz J.

Eur Urol. 2018 Jun 13. pii: S0302-2838(18)30424-X. doi: 10.1016/j.eururo.2018.05.035. [Epub ahead of print]

2.

Fast 3-T MR-guided transrectal prostate biopsy using an in-room tablet device for needle guide alignment: a feasibility study.

Overduin CG, Heidkamp J, Rothgang E, Barentsz JO, de Lange F, Fütterer JJ.

Eur Radiol. 2018 May 22. doi: 10.1007/s00330-018-5497-9. [Epub ahead of print]

PMID:
29789909
3.

Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System).

Panebianco V, Narumi Y, Altun E, Bochner BH, Efstathiou JA, Hafeez S, Huddart R, Kennish S, Lerner S, Montironi R, Muglia VF, Salomon G, Thomas S, Vargas HA, Witjes JA, Takeuchi M, Barentsz J, Catto JWF.

Eur Urol. 2018 May 10. pii: S0302-2838(18)30335-X. doi: 10.1016/j.eururo.2018.04.029. [Epub ahead of print] Review.

PMID:
29755006
4.

Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up.

Hamoen EHJ, Hoeks CMA, Somford DM, van Oort IM, Vergunst H, Oddens JR, Smits GA, Bokhorst LP, Witjes JA, Rovers MM, Hulsbergen-van de Kaa CA, Barentsz JO.

Eur Urol Focus. 2018 Jan 10. pii: S2405-4569(17)30295-X. doi: 10.1016/j.euf.2017.12.008. [Epub ahead of print]

PMID:
29331622
5.

A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection.

Hendriks RJ, van der Leest MMG, Dijkstra S, Barentsz JO, Van Criekinge W, Hulsbergen-van de Kaa CA, Schalken JA, Mulders PFA, van Oort IM.

Prostate. 2017 Oct;77(14):1401-1407. doi: 10.1002/pros.23401. Epub 2017 Aug 29.

PMID:
28853167
6.

Characteristics of Prostate Cancer Found at Fifth Screening in the European Randomized Study of Screening for Prostate Cancer Rotterdam: Can We Selectively Detect High-grade Prostate Cancer with Upfront Multivariable Risk Stratification and Magnetic Resonance Imaging?

Alberts AR, Schoots IG, Bokhorst LP, Drost FH, van Leenders GJ, Krestin GP, Dwarkasing RS, Barentsz JO, Schröder FH, Bangma CH, Roobol MJ.

Eur Urol. 2017 Jun 21. pii: S0302-2838(17)30514-6. doi: 10.1016/j.eururo.2017.06.019. [Epub ahead of print]

PMID:
28647216
7.

Ultra-small superparamagnetic iron oxides for metastatic lymph node detection: back on the block.

Fortuin AS, Brüggemann R, van der Linden J, Panfilov I, Israël B, Scheenen TWJ, Barentsz JO.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2018 Jan;10(1). doi: 10.1002/wnan.1471. Epub 2017 Apr 6. Review.

8.

Time to enhancement derived from ultrafast breast MRI as a novel parameter to discriminate benign from malignant breast lesions.

Mus RD, Borelli C, Bult P, Weiland E, Karssemeijer N, Barentsz JO, Gubern-Mérida A, Platel B, Mann RM.

Eur J Radiol. 2017 Apr;89:90-96. doi: 10.1016/j.ejrad.2017.01.020. Epub 2017 Jan 20.

PMID:
28267555
9.

Prostate Imaging-Reporting and Data System Version 2 and the Implementation of High-quality Prostate Magnetic Resonance Imaging.

Barentsz J, de Rooij M, Villeirs G, Weinreb J.

Eur Urol. 2017 Aug;72(2):189-191. doi: 10.1016/j.eururo.2017.02.030. Epub 2017 Mar 3. No abstract available.

PMID:
28262414
10.

Results of Targeted Biopsy in Men with Magnetic Resonance Imaging Lesions Classified Equivocal, Likely or Highly Likely to Be Clinically Significant Prostate Cancer.

Venderink W, van Luijtelaar A, Bomers JG, van der Leest M, Hulsbergen-van de Kaa C, Barentsz JO, Sedelaar JP, Fütterer JJ.

Eur Urol. 2017 Feb 28. pii: S0302-2838(17)30110-0. doi: 10.1016/j.eururo.2017.02.021. [Epub ahead of print]

PMID:
28258784
11.

A multiparametric magnetic resonance imaging-based risk model to determine the risk of significant prostate cancer prior to biopsy.

van Leeuwen PJ, Hayen A, Thompson JE, Moses D, Shnier R, Böhm M, Abuodha M, Haynes AM, Ting F, Barentsz J, Roobol M, Vass J, Rasiah K, Delprado W, Stricker PD.

BJU Int. 2017 Dec;120(6):774-781. doi: 10.1111/bju.13814. Epub 2017 Mar 31.

PMID:
28207981
12.

Why and Where do We Miss Significant Prostate Cancer with Multi-parametric Magnetic Resonance Imaging followed by Magnetic Resonance-guided and Transrectal Ultrasound-guided Biopsy in Biopsy-naïve Men?

Schouten MG, van der Leest M, Pokorny M, Hoogenboom M, Barentsz JO, Thompson LC, Fütterer JJ.

Eur Urol. 2017 Jun;71(6):896-903. doi: 10.1016/j.eururo.2016.12.006. Epub 2017 Jan 4.

PMID:
28063613
13.

Intranodal signal suppression in pelvic MR lymphography of prostate cancer patients: a quantitative comparison of ferumoxtran-10 and ferumoxytol.

Debats OA, Fortuin AS, Meijer HJ, Hambrock T, Litjens GJ, Barentsz JO, Huisman HJ.

PeerJ. 2016 Oct 20;4:e2471. eCollection 2016.

14.

Assessing Metastatic Disease in Advanced Prostate Cancer: It's Time to Change Imaging.

Barentsz JO, Mulders P, Gerritsen W, Fütterer JJ.

Eur Urol. 2017 Jan;71(1):93-95. doi: 10.1016/j.eururo.2016.08.045. Epub 2016 Aug 29. No abstract available.

PMID:
27595376
15.

Comparing Three Different Techniques for Magnetic Resonance Imaging-targeted Prostate Biopsies: A Systematic Review of In-bore versus Magnetic Resonance Imaging-transrectal Ultrasound fusion versus Cognitive Registration. Is There a Preferred Technique?

Wegelin O, van Melick HHE, Hooft L, Bosch JLHR, Reitsma HB, Barentsz JO, Somford DM.

Eur Urol. 2017 Apr;71(4):517-531. doi: 10.1016/j.eururo.2016.07.041. Epub 2016 Aug 25. Review.

PMID:
27568655
16.

MRI-guided focal laser ablation for prostate cancer followed by radical prostatectomy: correlation of treatment effects with imaging.

Bomers JGR, Cornel EB, Fütterer JJ, Jenniskens SFM, Schaafsma HE, Barentsz JO, Sedelaar JPM, Hulsbergen-van de Kaa CA, Witjes JA.

World J Urol. 2017 May;35(5):703-711. doi: 10.1007/s00345-016-1924-1. Epub 2016 Aug 19.

17.

PI-RADS Version 2: A Pictorial Update.

Purysko AS, Rosenkrantz AB, Barentsz JO, Weinreb JC, Macura KJ.

Radiographics. 2016 Sep-Oct;36(5):1354-72. doi: 10.1148/rg.2016150234. Epub 2016 Jul 29. Review.

PMID:
27471952
18.

Visibility of prostate cancer on transrectal ultrasound during fusion with multiparametric magnetic resonance imaging for biopsy.

van de Ven WJ, Sedelaar JP, van der Leest MM, Hulsbergen-van de Kaa CA, Barentsz JO, Fütterer JJ, Huisman HJ.

Clin Imaging. 2016 Jul-Aug;40(4):745-50. doi: 10.1016/j.clinimag.2016.02.005. Epub 2016 Feb 6.

PMID:
27317220
19.

Reply to Erik Rud and Eduard Baco's Letter to the Editor re: Re: Jeffrey C. Weinreb, Jelle O. Barentsz, Peter L. Choyke, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol 2016;69:16-40.

Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, Margolis D, Shtern F, Padhani AR, Tempany CM, Thoeny HC, Verma S, Weinreb JC.

Eur Urol. 2016 Nov;70(5):e137-e138. doi: 10.1016/j.eururo.2016.04.016. Epub 2016 Apr 27. No abstract available.

PMID:
27130148
20.

MR-targeted TRUS prostate biopsy using local reference augmentation: initial experience.

van de Ven WJ, Venderink W, Sedelaar JP, Veltman J, Barentsz JO, Fütterer JJ, Cornel EB, Huisman HJ.

Int Urol Nephrol. 2016 Jul;48(7):1037-45. doi: 10.1007/s11255-016-1283-2. Epub 2016 Apr 11.

Supplemental Content

Loading ...
Support Center